These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1625412)

  • 21. [ACE-inhibitors in renal protection].
    Barna I
    Orv Hetil; 2006 Jun; 147(22):1019-23. PubMed ID: 16913091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation.
    Häggström J; Hansson K; Karlberg BE; Kvart C; Madej A; Olsson K
    Am J Vet Res; 1996 Nov; 57(11):1645-52. PubMed ID: 8915446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Atrial fibrillation: potential therapeutic interventions in the renin-angiotensin-aldosterone system].
    Dabrowski R; Szwed H
    Kardiol Pol; 2007 Apr; 65(4):440-5. PubMed ID: 17530565
    [No Abstract]   [Full Text] [Related]  

  • 24. Mechanisms of disease: local renin-angiotensin-aldosterone systems and the pathogenesis and treatment of cardiovascular disease.
    Re RN
    Nat Clin Pract Cardiovasc Med; 2004 Nov; 1(1):42-7. PubMed ID: 16265259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
    Lim S
    Acta Med Indones; 2008 Jan; 40(1):34-7. PubMed ID: 19054878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The renin-angiotensin-aldosterone system in atrial fibrillation: a new therapeutic target?
    Freestone B; Beevers DG; Lip GY
    J Hum Hypertens; 2004 Jul; 18(7):461-5. PubMed ID: 14973520
    [No Abstract]   [Full Text] [Related]  

  • 27. Heart failure: how important is cellular sequestration? The role of the renin-angiotensin-aldosterone system.
    De Mello WC
    J Mol Cell Cardiol; 2004 Aug; 37(2):431-8. PubMed ID: 15276013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
    Toto R; Palmer BF
    Am J Nephrol; 2008; 28(3):372-80. PubMed ID: 18073461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The renin-angiotensin system as a target for therapeutic intervention.
    Swales JD
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S1-5. PubMed ID: 7898088
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tissue renin angiotensin systems: theoretical implications for the development of hyperkalemia using angiotensin-converting enzyme inhibitors.
    Schlueter W; Keilani T; Batlle DC
    Am J Med Sci; 1994 Feb; 307 Suppl 1():S81-6. PubMed ID: 8141171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitors of the renin-angiotensin system.
    Brunner HR; Nussberger J; Waeber B
    Arzneimittelforschung; 1993 Feb; 43(2A):274-8. PubMed ID: 8498978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renin-angiotensin system and atherothrombotic disease: from genes to treatment.
    Jacoby DS; Rader DJ
    Arch Intern Med; 2003 May; 163(10):1155-64. PubMed ID: 12767951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapeutic possibilities for the inhibition of the renin-angiotensin-aldosterone system].
    Abrahám G; Légrády P
    Orv Hetil; 2003 May; 144(18 Suppl 1):892-5. PubMed ID: 12785232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pathophysiological and clinical implications of AT(1)/AT(2) angiotensin II receptors in heart failure and coronary and renal failure].
    Sandmann S; Unger T
    Drugs; 2002; 62 Spec No 1():43-52. PubMed ID: 12036388
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect of the cardiac renin-angiotensin system on hypertrophy].
    Ertl G; Schorb W; Gaudron P; Hu K
    Z Kardiol; 1996; 85 Suppl 6():233-40. PubMed ID: 9064970
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The renin-angiotensin-aldosterone system, angiotensin I converting enzyme, and the ACE-inhibitors. Historical perspective and recent findings].
    Gensini GF; Lippi D; Conti AA
    Recenti Prog Med; 2002 Oct; 93(10):544-53. PubMed ID: 12405014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic kidney disease: tipping the scale to the benefit of angiotensin-converting enzyme inhibitors in patients with coronary artery disease.
    McCullough PA
    Circulation; 2006 Jul; 114(1):6-7. PubMed ID: 16818827
    [No Abstract]   [Full Text] [Related]  

  • 39. Interaction of beta-blockers and angiotensin receptor blockers/ACE inhibitors in heart failure.
    Cohn JN
    J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):137-9. PubMed ID: 14608516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blockade of the renin-angiotensin-aldosterone system with combination angiotensin receptor antagonist and ACE inhibitor therapy: observations from Val-HeFT and CALM.
    Chin BS; Lip GY
    J Hum Hypertens; 2001 Feb; 15(2):89-92. PubMed ID: 11317186
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.